The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans (Q38752520)

6 September 2017

The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans (English)

1 reference

6 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Fabio Nascimbeni

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Amedeo Lonardo

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

4

Enrica Baldelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

3

Dante Romagnoli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

26 February 2016

1 reference

6 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

291-319

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921205%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921205%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12325-016-0306-9

31 May 2020

exact match

0 references

cites work

Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

From NAFLD in clinical practice to answers from guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Nonalcoholic fatty liver disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Review article: hepatic steatosis and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Non-alcoholic fatty liver disease: the role of nuclear receptors and circadian rhythmicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Liver and diabetes. A vicious circle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Transcriptional regulation of hepatic lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

From the metabolic syndrome to NAFLD or vice versa?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

A 360-degree overview of paediatric NAFLD: recent insights.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Roles of PPARs in NAFLD: potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Experimental models of non-alcoholic fatty liver disease in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Phenotyping the effect of diet on non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Reversal of high-fat diet-induced hepatic steatosis by n-3 LCPUFA: role of PPAR-α and SREBP-1c

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

N-3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

PPARgamma-mediated insulin sensitization: the importance of fat versus muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Meta-analysis of associations between the peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and susceptibility to nonalcoholic fatty liver disease, rheumatoid arthritis, and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

PPARdelta regulates glucose metabolism and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Bile acids, obesity, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Bile acids: chemistry, physiology, and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Role of bile acids and bile acid receptors in metabolic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Genetic variation in NR1H4 encoding the bile acid receptor FXR determines fasting glucose and free fatty acid levels in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after sleeve gastrectomy in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

FXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

NHE1 deficiency in liver: implications for non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The liver X receptor: a master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Lipid regulators during atherogenesis: expression of LXR, PPAR, and SREBP mRNA in the human aorta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Liver X receptor β controls thyroid hormone feedback in the brain and regulates browning of subcutaneous white adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Molecular pathways: sterols and receptor signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Liver X receptor activation increases hepatic fatty acid desaturation by the induction of SCD1 expression through an LXRα-SREBP1c-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Liver X receptor α-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

A liver-selective LXR inverse agonist that suppresses hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Sterile inflammation in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Review article: non-alcoholic fatty liver disease and osteoporosis--clinical and molecular crosstalk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Statin use and non-alcoholic steatohepatitis in at risk individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPARα.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Activation of PPARα ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Short-Chain Fatty Acids Protect Against High-Fat Diet-Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

NASH (Nonalcoholic steatohepatitis): A case of multiorganelle failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Nonalcoholic fatty liver disease in lean individuals in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Liver X receptors as integrators of metabolic and inflammatory signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Coordinate regulation of neutrophil homeostasis by liver X receptors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Factors associated with significant liver fibrosis assessed using transient elastography in general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Potential for statins in the chemoprevention and management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Obesity-associated improvements in metabolic profile through expansion of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Non-alcoholic fatty liver disease and risk of cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Chemopreventive strategies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

A "systems medicine" approach to the study of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Understanding nutritional interventions and physical exercise in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Aspirin use is associated with lower indices of liver fibrosis among adults in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Statins and primary liver cancer: a meta-analysis of observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Cancer risk in HBV patients with statin and metformin use: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Nuclear receptors reverse McGarry's vicious cycle to insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Current efforts and trends in the treatment of NASH

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Nuclear receptors: how do they position in non-alcoholic fatty liver disease treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9

Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-016-0306-9